AMNEAL PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$57.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $66.66M, a 46.11% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$124.58M.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $18.58M, a 71.96% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $69.75M, a 48.87% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $21.32M, a 90.93% decline from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $235.13M.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$94.45M, a 186.20% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $109.57M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $66.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$57.92M 10-Q · filed 2026-08-06 | -$39.34M derived: sum of 3 quarters · filed 2026-08-06 | $30.41M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$124.58M 10-Q · filed 2026-05-07 | -$106.00M derived: sum of 2 quarters · filed 2026-05-07 | -$36.25M derived: sum of 3 quarters · filed 2026-05-07 | $9.37M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $18.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $88.33M derived: sum of 2 quarters · filed 2026-02-27 | $133.95M derived: sum of 3 quarters · filed 2026-08-06 | $21.32M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $69.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $115.37M derived: sum of 2 quarters · filed 2026-08-06 | $2.74M 10-Q · filed 2025-11-06 | $69.00M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $45.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$67.00M 10-Q · filed 2026-08-06 | -$748.00K derived: sum of 3 quarters · filed 2026-08-06 | $46.10M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$112.63M 10-Q · filed 2026-05-07 | -$46.37M derived: sum of 2 quarters · filed 2026-05-07 | $483.00K derived: sum of 3 quarters · filed 2026-05-07 | $60.34M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $66.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $113.11M derived: sum of 2 quarters · filed 2026-02-27 | $172.96M derived: sum of 3 quarters · filed 2026-02-27 | $235.13M 10-K · filed 2026-02-27 | ||
| 2024-09-30 | $46.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $106.70M derived: sum of 2 quarters · filed 2025-11-06 | $168.88M 10-Q · filed 2025-11-06 | $149.12M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-06-30 | $59.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $122.03M 10-Q · filed 2025-08-07 | $102.27M derived: sum of 3 quarters · filed 2026-02-27 | $135.34M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-03-31 | $62.17M 10-Q · filed 2025-05-07 | $42.41M derived: sum of 2 quarters · filed 2026-02-27 | $75.49M derived: sum of 3 quarters · filed 2026-02-27 | $118.21M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2023-12-31 | -$19.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $13.31M derived: sum of 2 quarters · filed 2026-02-27 | $56.04M derived: sum of 3 quarters · filed 2026-02-27 | -$94.45M 10-K · filed 2026-02-27 | ||
| 2023-09-30 | $33.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $75.80M derived: sum of 2 quarters · filed 2024-11-12 | -$74.69M 10-Q · filed 2024-11-12 | -$130.55M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | $42.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$107.76M 10-Q · filed 2024-08-09 | -$163.63M derived: sum of 3 quarters · filed 2025-02-28 | -$272.14M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-03-31 | -$150.48M 10-Q · filed 2024-05-08 | -$206.35M derived: sum of 2 quarters · filed 2025-02-28 | -$314.86M derived: sum of 3 quarters · filed 2025-02-28 | $7.86M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2022-12-31 | -$55.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$164.38M derived: sum of 2 quarters · filed 2025-02-28 | $158.34M derived: sum of 3 quarters · filed 2025-02-28 | $109.57M 10-K · filed 2025-02-28 | ||
| 2022-09-30 | -$108.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $214.21M derived: sum of 2 quarters · filed 2023-11-09 | $165.44M 10-Q · filed 2023-11-09 | $154.32M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-06-30 | $322.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $273.95M 10-Q · filed 2023-08-08 | $262.83M derived: sum of 3 quarters · filed 2024-03-14 | $251.15M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-03-31 | -$48.78M 10-Q · filed 2023-05-09 | -$59.89M derived: sum of 2 quarters · filed 2024-03-14 | -$71.57M derived: sum of 3 quarters · filed 2024-03-14 | -$55.48M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2021-12-31 | -$11.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$22.80M derived: sum of 2 quarters · filed 2024-03-14 | -$6.71M derived: sum of 3 quarters · filed 2024-03-14 | -$43.93M 10-K · filed 2024-03-14 | ||
| 2021-09-30 | -$11.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $4.41M derived: sum of 2 quarters · filed 2022-11-07 | -$32.82M 10-Q · filed 2022-11-07 | -$54.25M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2021-06-30 | $16.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$21.14M 10-Q · filed 2022-08-08 | -$42.57M derived: sum of 3 quarters · filed 2023-03-03 | -$36.00M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2021-03-31 | -$37.23M 10-Q · filed 2022-05-06 | -$58.66M derived: sum of 2 quarters · filed 2023-03-03 | -$52.09M derived: sum of 3 quarters · filed 2023-03-03 | -$71.76M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2020-12-31 | -$21.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$14.87M derived: sum of 2 quarters · filed 2023-03-03 | -$34.53M derived: sum of 3 quarters · filed 2023-03-03 | $307.00K 10-K · filed 2023-03-03 | ||
| 2020-09-30 | $6.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$13.10M derived: sum of 2 quarters · filed 2021-11-08 | $21.74M 10-Q · filed 2021-11-08 | $25.41M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | -$19.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $15.17M 10-Q · filed 2021-08-09 | $18.85M derived: sum of 3 quarters · filed 2022-03-01 | $18.45M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $34.84M 10-Q · filed 2021-05-07 | $38.51M derived: sum of 2 quarters · filed 2022-03-01 | $38.12M derived: sum of 3 quarters · filed 2022-03-01 | $23.89M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.28M derived: sum of 2 quarters · filed 2022-03-01 | -$10.95M derived: sum of 3 quarters · filed 2022-03-01 | -$10.26M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | -$394.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$14.63M derived: sum of 2 quarters · filed 2020-11-06 | -$13.93M 10-Q · filed 2020-11-06 | -$40.62M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | -$14.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$13.54M 10-Q · filed 2020-08-06 | -$40.23M derived: sum of 3 quarters · filed 2021-03-01 | -$86.72M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-03-31 | $695.00K 10-Q · filed 2020-05-11 | -$25.99M derived: sum of 2 quarters · filed 2021-03-01 | -$72.48M derived: sum of 3 quarters · filed 2021-03-01 | -$68.18M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | -$26.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$73.18M derived: sum of 2 quarters · filed 2021-03-01 | -$68.87M derived: sum of 3 quarters · filed 2021-03-01 | -$53.55M 10-K · filed 2021-03-01 | -$55.21M 10-K · filed 2019-03-01 | |
| 2018-09-30 | -$46.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$42.18M derived: sum of 2 quarters · filed 2019-11-07 | -$26.86M 10-Q · filed 2019-11-07 | -$14.34M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | $4.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $19.63M 10-Q · filed 2019-08-05 | $15.30M 10-Q · filed 2018-08-09 | $32.15M derived: sum of 3 quarters · filed 2020-03-02 | $41.55M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | $15.32M 10-Q · filed 2019-05-09 | $27.85M derived: sum of 2 quarters · filed 2020-03-02 | $37.24M derived: sum of 3 quarters · filed 2020-03-02 | |||
| 2017-12-31 | $12.52M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $21.92M derived: sum of 2 quarters · filed 2020-03-02 | $18.11M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | $9.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $5.58M 10-Q · filed 2018-11-07 | ||||
| 2017-06-30 | -$3.81M 10-Q · filed 2018-08-09 | |||||
| 2016-12-31 | $6.26M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |